NCT05268068View on ClinicalTrials.gov

A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

April 26, 2020

Study Completion Date

April 26, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

Risankizumab

Intravenous (IV) Infusion

DRUG

Risankizumab

Subcutaneous (SC) Injection

Trial Locations (1)

200031

Shanghai Xuhui Central Hospital /ID# 212830, Shanghai

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY